Share on StockTwits

ImmunoGen (NASDAQ:IMGN) has earned an average rating of “Hold” from the eight ratings firms that are presently covering the company, Stock Ratings News reports. Two analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $18.43.

Separately, analysts at Morgan Stanley initiated coverage on shares of ImmunoGen in a research note on Wednesday, June 25th. They set an “underweight” rating and a $10.00 price target on the stock.

ImmunoGen (NASDAQ:IMGN) traded up 5.16% on Tuesday, hitting $12.43. The stock had a trading volume of 254,992 shares. ImmunoGen has a 52 week low of $10.28 and a 52 week high of $18.34. The stock has a 50-day moving average of $11.29 and a 200-day moving average of $13.04. The company’s market cap is $1.068 billion.

ImmunoGen (NASDAQ:IMGN) last announced its earnings results on Friday, August 1st. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.32) by $0.51. The company had revenue of $5.74 million for the quarter, compared to the consensus estimate of $9.72 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Analysts expect that ImmunoGen will post $-0.72 EPS for the current fiscal year.

ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.

Receive News & Ratings for ImmunoGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.